Polyclonality & Initial HIV- specific CD4 clone size determine outcome of infection Hester Korthals Altes Lab. Immunologie Tissulaire et Cellulaire Hôpital.

Slides:



Advertisements
Similar presentations
Purging the HIV-1 Reservoir Through the Disruption of the PD-1 Pathway
Advertisements

Chapter15 B cell mediated immune response. B cells mediated immune response Humoral immunity(HI) or antibody mediated immunity: The total immunological.
Immunology in Head and Neck Cancer Stephanie Cordes, MD Christopher Rassekh, MD February 11, 1998.
IL-2 as the adjuvant in FMD vaccine Chunxia su , ph.D. Ningxia Medical University Yinchuan , China.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 67 Review of the Immune System.
Professeur Patrice DEBRE Laboratoire d’Immunologie Cellulaire et Tissulaire INSERM U945 Hôpital Pitié-Salpêtrière; Paris "Vers un vaccin contre le SIDA.
Myeloid dendritic cells and HIV latency in resting T-cells Nitasha A Kumar, Vanessa A Evans, Suha Saleh, Candida de Fonseca Pereira, Paula Ellenberg, Paul.
High Affinity HIV-1 Specific CTL Become Exhausted in Early HIV-1 Infection High Affinity HIV-1 Specific CTL Become Exhausted in Early HIV-1 Infection Abstract.
Stochastic Stage-structured Modeling of the Adaptive Immune System Dennis L. Chao 1, Miles P. Davenport 2, Stephanie Forrest 1, and Alan S. Perelson 3.
1 How T cells recognize antigen: The T Cell Receptor (TCR) Lecture 11, MCB 150 Laurent Coscoy.
Immunology of HPV Infection Craig Woodworth Department of Biology Clarkson University Potsdam, NY.
6.4 B cells and humoral immunity
Monoclonal Antibodies Large scale production and their implications in AIDS research.
Treg exert differential effects on the proliferation and differentiation of CD8 T cell subsets in chronic HIV-1 infection M. Nikolova 1, M. Muhtarova 1,
The Adaptive Immune System and Humoral Immunity
Acute HIV Infection Translating Pathogenesis into Opportunity Eric S. Rosenberg, M.D. Associate Professor of Medicine Massachusetts General Hospital Harvard.
Eric S. Rosenberg, M.D. Associate Professor of Medicine Massachusetts General Hospital Harvard Medical School
Copyright © 2006 Pearson Education, Inc., publishing as Benjamin Cummings Chapter 14 Specific Immunity (adaptive immunity)
Autologous T-cell therapy based on a lentiviral vector expressing long antisense RNA targeted against HIV-1 env gene influences HIV replication and evolution.
18.3 Viral Diseases KEY CONCEPT Some viral diseases can be prevented with vaccines.
Phagocyte. B cells Receptor B Cell Naïve B cell B cells and antibodies daughter cells produce antibodies phagocyte consumes an antibody coated virus.
Chapter 15 B cell mediated immune response
Novel Approaches: Treatment and HIV Pathogenesis L. Trautmann, Ph.D. VGTI Florida.
Acquiring Immunity Long Term Protection. Individual Activity (means no talking) Read Acquiring Specific Immunity at top of p317 of Biology 2.
Immunology We have specific and a non-specific response sytems Non-Specific = barriers, like skin and mucus, HCl in the stomach, and phagocytosis. Specific.
KEY CONCEPT Some viral diseases can be prevented with vaccines.
Chapter 15 B cell mediated immune response. B Cells Lymphocytes that react directly with antigens Require stimulation from Helper T Cells Offspring become.
Primary HIV-1 Infection Pathogenesis, Diagnosis, and Treatment Summary of Evidence Martin Markowitz M.D. Clinical Director and Staff Investigator Aaron.
Functional cure after long term HAART initiated during early HIV infection - a case study. van Lunzen J. 1,2, Schulze zur Wiesch J. 1,2, Schumacher U.
Adaptive immunity – B cell
HIV pathogenesis The course of HIV infection 1. Acute Phase 2. Intermediate (asymptomatic) phase -viral load stabilizes at a “set point”. 3. Late (symptomatic)
Retrovirus. Retroviridae –Retrovirus HTLV (human T-cell lymphotropic virus) –Lentivirus HIV.
Evolution of the Functional Profile of HIV-Specific CD8+ T cells in a Cohort of Long Term Nonprogressors M López, N Rallón, A Peris, M Salgado, B Rodés,
HIV/AIDS.
T-cell activation positively correlates with cell-associated HIV-DNA level in PBMCs in viremic patients with acute or chronic HIV-1 infection Laurence.
THE IMMUNOPATHOGENESIS OF HIV INFECTION Lymphotropic virus.
Immune reconstitution Anjie Zhen, PhD
HUMAN IMMUNODEFICIENCY VIRUS AND ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)
The Negative Checkpoint Receptor TIGIT Marks Exhausted T cells During SIV Infection and Correlates with SIV Disease Progression Gabriela Webb Vaccine and.
CATEGORY: VACCINES & THERAPEUTICS HIV-1 Vaccines Shokouh Makvandi-Nejad, University of Oxford, UK HIV-1 Vaccines © The copyright for this work resides.
HAART Initiation Within 2 Weeks of Seroconversion Associated With Virologic and Immunologic Benefits Slideset on: Hecht FM, Wang L, Collier A, et al. A.
40-2 The Immune System Pg Introduction 1. The immune system fights infection by producing cells that inactivate (DEFEAT!) foreign substances/cells.
HIV ‐ 1 replication activates CD4 + T cells with specificities for persistent herpes viruses by Anna Haas, Manuela Rehr, Frederik Graw, Peter Rusert, Walter.
Martine Bruley Rosset UMR S 938 INSERM Hôpital St Antoine Paris France
HIV-1 Vaccines Shokouh Makvandi-Nejad, University of Oxford, UK
HIV Cure: Current Status and Future Perspectives
Specific Defenses: Immunity
Immune system-Acquired/Adaptive immunity
3.1.6 Immunology Review L.O: To recall the second and third lines of defence Oh! What’s occurring?
KEY CONCEPT Some viral diseases can be prevented with vaccines.
Didier Trono, Flavia Marzetta  Cell Host & Microbe 
Les Lang  Gastroenterology  Volume 133, Issue 1, (July 2007)
Figure 2 Systemic immune responses to cryptococcal antigen
Figure 2 Peptide vaccination using TAA-derived long peptides
Humoral & Cell-mediated immunity
Les Lang  Gastroenterology  Volume 133, Issue 1, (July 2007)
Differentiation and Functions of CD8+ Effector T Cells
Immune System Practice Test
Immune System Practice Test
Human Immunodeficiency Virus Controllers: Mechanisms of Durable Virus Control in the Absence of Antiretroviral Therapy  Steven G. Deeks, Bruce D. Walker 
Humoral and Cell Mediated Immunity
Immune System Practice Test
Immune reconstitution inflammatory syndrome (IRIS) associated with Mycobacterium tuberculosis (TB) infection. a) In healthy individuals in response to.
Immune System Flashcards
KEY CONCEPT Some viral diseases can be prevented with vaccines.
Theoretical Immunology: Aging
Biomarkers as Endpoints
KEY CONCEPT Some viral diseases can be prevented with vaccines.
KEY CONCEPT Some viral diseases can be prevented with vaccines.
Presentation transcript:

Polyclonality & Initial HIV- specific CD4 clone size determine outcome of infection Hester Korthals Altes Lab. Immunologie Tissulaire et Cellulaire Hôpital Pitié-Salpêtrière, Paris, France

Early events in HIV infection determine viral setpoint and subsequent disease progression (Staprans et al. ‘99, Lifson et al. ‘97) Breadth of CD8 T cell repertoire correlates negatively with progression (Pantaleo et al. ‘97) Model HIV infection to explore how viral setpoint depends on:  CD4 helper clone size at infection  Polyclonality of the response Observations:

Specific CD4 cells important targets of infection (Miedema et al. ’88, Laurence et al. ’89, and Douek et al. 02) Importance for priming and establishment of memory CD8 response (resp. Ridge et al. ‘98/ Livingstone & Kuhn ’99 and Borrow et al.) Association CD4 T helper response with disease progression / control (Rosenberg et al., Pitcher et al. ‘99) HIV-specific CD4: HIV targets and mediators of immune response

The model Infection Virus Source T Non-specific CD4 and other targets cells I Infected CD4 T cell Lytic Infection HIV- specific CD4 T cells (i clones) HiHi Non-lytic CTL response proportional to Th response

The model / Mathematics

Characteristics of HIV-specific CD4 clones Clones differ in functional avidity:  1 = “responsiveness to Ag” = amount of antigen needed for half- maximum proliferation of H 1. Responsiveness H 2 scaled to responsiveness  1 of H 1 (  2 =g  1 ). H 1 is dominant, because g>1. Competition within clones; Competition between clones only indirectly, through Ag stimulation

MONOCLONAL SYSTEM: Virus infectivity and outcome of infection No T helpers Immune control: 1 non-lytic clone

Initial events crucial High initial H 0 : Immune control Low initial H 0 : No Immune control  =0.05; T 0 =40; I 0 =1

No T helpers MONOCLONAL SYSTEM: Th avidity and outcome of infection Immune control: 1 non-lytic clone

2 LYTIC CLONES: Th avidity and outcome of infection 2 lytic clones 1 lytic clone No T helpers

1 lytic clone 1 non-lytic, 1 lytic clone 2 DIFFERENT CLONES: Th avidity and outcome of infection No T helpers

Conclusions I Bistability: Initial race between CD4 T helpers and HIV can determine the outcome of infection; importance dual role CD4 H - early therapy preserves CD4 and associated CTL response against HIV (Oxenius et al., 2000); - CD4 H induced by vaccination is beneficial (Heeney 2002). Probability of n-stability occurring highest with only non-lytic or with “specialised” responses (high-avidity lytic, low-avidity non-lytic)

Conclusions II Variation in viral setpoints can be ex- plained by: –n-stability across patients with same HLA-type –differences in avidity of clones across patients with different HLA-type Implications for structured therapy interruptions: possible to stimulate extra clones of intermediate avidity

Acknowledgements Rob de Boer Theoretical Biology, Utrecht University, the Netherlands Ruy Ribeiro Theoretical Biology and Biophysics, Los Alamos National Laboratories Research supported by a Marie Curie Fellowship under the European Community Programme Quality of Life